858 — Extrawell Pharmaceutical Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapSucker Stock

Market Cap
HK$139.20m
Enterprise Value
HK$115.92m
Revenue
HK$51.48m

Annual income statement for Extrawell Pharmaceutical Holdings, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	HKAS	HKAS	HKAS	HKAS	HKAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	73.9	72.6	59.1	55.4	51.5
Cost of Revenue
Gross Profit	37.6	31.1	28.8	21.9	22.7
Selling / General / Administrative Expenses
Operating Interest Expense / Income
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	-75.3	-77.8	198	-194	1,008
Operating Profit	149	150	-138	249	-957
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	132	131	-160	225	-986
Provision for Income Taxes
Net Income After Taxes	131	130	-162	224	-978
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	131	129	-163	223	-980
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	144	145	-163	245	-980
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.044	0.044	-0.068	0.102	-0.395